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Abstract
Background: A registry of patients with cervical dystonia (Cervical Dystonia Patient Registry for Observation of
onaBotulinumtoxinA Efficacy [CD PROBE]) was initiated to capture data regarding physician practices and patient
outcomes with onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA, USA). Methods and baseline demographics
from an interim analysis are provided.
Methods/Design: This is a prospective, multicenter, clinical registry in the United States enrolling subjects with
cervical dystonia (CD) who are toxin naïve and/or new to the physicians’ practices, or who had been in a clinical
trial but received their last injection ≥ 16 weeks prior to enrollment. Subjects are followed over 3 injection cycles of
onabotulinumtoxinA, with assessments at time of injection and 4-6 weeks later. Information on physician’s practice,
patient demographics, CD disease history, duration of treatment intervals and neurotoxin dose, dilution, use of
electromyography, and muscles injected are collected. Outcomes are assessed by physicians and subjects using
various questionnaires.
Discussion: This ongoing registry includes 609 subjects with the following baseline data: 75.9% female, 93.6%
Caucasian, mean age 57.6 ± 14.3, age at symptom onset 48.3 ± 16.2, and time to diagnosis 5.4 ± 8.6 years, with an
additional 1.0 ± 3.5 years before treatment. Of those employed at the time of diagnosis, 36.6% stopped working as
a result of CD. CD PROBE, the largest clinical registry of CD treatment, will provide useful data on current treatment
practices with onabotulinumtoxinA, potentially leading to refinements for optimization of outcomes.
Trial registration: NCT00836017
Background
Cervical dystonia (CD), the most common form of adult-
onset focal dystonia, is manifested by sustained, involun-
tary contractions of the cervical musculature [1]. Patients
usually present with pain and postural changes of the
neck, often associated with irregular head tremor (dys-
tonic tremor) [2]. Impaired neck mobility, chronic pain,
and a reduction in the patient’s self-image may adversely
impact quality of life and result in disability [3,4].
Physicians and patients had few treatment options
prior to the introduction of botulinum toxin for CD
over a quarter century ago [5]. Supported with evidence
from randomized controlled trials and meta-analyses,
botulinum toxin has become the treatment of choice for
CD [6,7]. An evidence-based review by the Therapeutics
and Technology Assessment Subcommittee of the
American Academy of Neurology concluded that botuli-
num toxin should be offered as a treatment option to
patients with CD, a level A recommendation [8]. Botuli-
num toxin exerts its effect by inhibiting the presynaptic
release of acetylcholine from peripheral terminals of
motor neurons, thus causing chemodenervation and
weakness of the injected muscle [9].
Four botulinum toxin products are approved for CD.
Three are serotype A (onabotulinumtoxinA [BOTOX®,
Allergan, Inc., Irvine, CA, USA]; abobotulinumtoxinA
[Dysport®, Ipsen, Paris, France]; incobotulinumtoxinA
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[Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt,
Germany]) and one is serotype B (rimabotulinumtoxinB
[Myobloc®/Neurobloc®, Solstice Neurosciences, San
Francisco, CA, USA]). Each differs in molecular struc-
ture, formulation, and clinical profiles. There is no inter-
national potency reference standard for botulinum
toxins and each formulation of botulinum toxin is dif-
ferent. Therefore, the units of activity are specific to
each product and not interchangeable with those of any
other botulinum toxins [10].
The objective of this paper is to describe the rationale,
study design, and baseline characteristics of patients par-
ticipating in Cervical Dystonia Patient Registry for Obser-
vation of onabotulinumtoxinA Efficacy (CD PROBE;
NCT00836017), a large observational study designed to
capture data on the clinical presentation, dosing of ona-
botulinumtoxinA, and treatment outcomes in patients
with CD. Despite years of use in thousands of patients
and clinical evidence from randomized controlled trials,
questions remain regarding the optimal use of onabotuli-
numtoxinA for CD. In disorders, such as CD, where
there is variability in clinical presentation and severity of
symptoms, as well as a variety of comorbidities and use
of concomitant medications, optimal treatment schemas
may not be available from controlled clinical trials.
Experience indicates that proper muscle selection and
dose are key determinants for a good response. However,
in current practice, there is lack of consensus regarding
technical aspects of the use of onabotulinumtoxinA, such
as the optimal dose, dilution ratios, number of injection
sites, combination and number of muscles to inject, dos-
ing interval, and targeting procedure [10-15]. Determi-
nants that impact treatment decisions, such as disease
severity and clinical presentation, have not been clearly
identified. Furthermore, specialists involved in the treat-
ment of CD, including neurologists and physiatrists, may
use different approaches to treatment and injection tech-
niques, for which the effect on outcomes is unknown. A
number of studies have shown that CD adversely affects
quality of life [4,16,17] and symptom relief following
botulinum toxin treatment results in improvement
[18-22]. However, many quality of life measures used in
prior clinical trials were not disease-specific and were not
sensitive enough to detect clinically relevant changes.
By capturing real-world treatment practices and
patient outcomes, CD PROBE will attempt to answer a
number of clinical questions noted above or, at mini-
mum, generate reasonable hypotheses for further inves-
tigation, to optimize outcomes among CD patients
being treated with onabotulinumtoxinA.
Methods/Design
The primary objectives for CD PROBE, as predefined by
the CD PROBE Charter Committee (JJ, MS, CA, PDC,
CC, and MB) are to determine if:
• the presentation of anatomical subtypes of CD cor-
relate with the Toronto Western Spasmodic Torti-
collis Rating Scale (TWSTRS) scores and global
assessment of severity rating;
• specific presentations of CD inform treatment
choices (muscles injected, number of sites injected,
dose, and dilution);
• there are clinically definable severity subtypes (e.g.
mild, moderate, severe) that correlate with CD
scales/questionnaires;
• a new pictorial version of a scale to assess disease
severity, the Pictorial Spasmodic Torticollis Rating
Scale (P-STRS), correlates with other measures and
is sensitive to change with treatment;
• the impact of disease and treatment affects quality
of life;
• there are potential predictors of outcomes, includ-
ing baseline presentation, treatment approach, injec-
tor’s practice characteristics, and adverse effects.
The CD PROBE Study
CD PROBE is a multicenter, national, prospective, stan-
dard-of-care, observational clinical registry designed to
capture real-world clinical practices of neurologists, phy-
siatrists, and other physicians who regularly treat CD.
Including a range of clinical practices will allow compari-
son of treatment patterns for CD between physician
groups having a wide range of experience in treating CD.
Subjects
This prospective clinical registry includes subjects with a
diagnosis of CD, who in the clinical judgment of the
investigator, are considered to be candidates for onabo-
tulinumtoxinA therapy and/or who are new to the phy-
sician’s practice or new to botulinum toxin therapy.
Subjects who had previously participated in a clinical
trial using botulinum toxin may be included if the time
since their last dose is greater than 16 weeks. Subjects
excluded are those planning elective surgery during the
study; women who are nursing, pregnant, or planning a
pregnancy; subjects with a history of poor compliance
with medical treatment; and any condition or situation
which, in the physician’s opinion, could place the sub-
ject at risk, confound the registry data, or interfere sig-
nificantly with the subject’s participation in the registry.
Institutional Review Board approval was granted at each
participating site and written informed consent will be
obtained from all patients prior to any study procedures
being performed.
Baseline information collected includes demographics;
history of CD diagnosis; and past treatments, comorbid-
ities, and medications, including over-the-counter
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medications. Although CD presents with mixed symp-
toms, the CD classification of the predominant feature
(anterocollis, lateralcollis, retrocollis, or torticollis) and
the predominant direction of pull is recorded. Informa-
tion is also collected that characterizes the physicians’
practice and their experience with botulinum toxin
(Table 1).
The aim of this study is to gain valuable information
on the current treatment of CD with various patient
types and different clinical practices, which will require
a large number of subjects to be enrolled. With 600
patients enrolled as of February 2011, it is anticipated
that more than 1,000 patients will be enrolled by the
end of 2011.
Visits and assessments
The study period includes 3 injection cycles of onabotu-
linumtoxinA. Subjects are evaluated for safety and effi-
cacy at each injection and at the peak effect 4 to 6
weeks following the injection. Follow-up visits after the
first and second injections are via a telephone interview
and follow-up after the third injection at the physician’s
office (Figure 1). Baseline data are collected prior to the
first injection. The dosing and injection pattern are
those customary for the practice of the physician. Infor-
mation is collected on the dilution of onabotulinumtox-
inA, dosing, use of electromyography, and muscles
injected.
A comprehensive evaluation of outcomes is made by
physicians and subjects using questionnaires that assess
disease-specific outcomes, severity and improvement of
symptoms, impact on overall well-being, quality of life,
and impact of CD on work productivity and utilization
of healthcare resources (Figure 1). The assessments that
are made by the physician include the following:
1. TWSTRS is a validated, disease-specific question-
naire that comprises 3 subscales assessing severity
(0 to 35), disability (0 to 30), and pain (0 to 20),
including a total score (0 to 85) [23]. It is the most
commonly used outcome measure in clinical trials of
CD and botulinum toxins [9].
2. P-STRS is a new, disease-specific tool being devel-
oped to assess CD severity. Based on the TWSTRS
severity subscale, P-STRS uses pictorial representa-
tions of the anatomical head and neck position. Pre-
liminary assessments indicate that it is a valid and
reliable tool that is sensitive to symptom improve-
ment following treatment [24].
3. Clinician Global Impression of Change (CGIC) is
a general questionnaire that provides the physician’s
assessment of the global impression of change using
a 7-point scale ranging from “very much improved”
to “very much worse” [25]. This questionnaire is
used to determine if the change is clinically
meaningful.
4. CD severity rating is the physician’s assessment of
the severity (mild, moderate, or severe) of the symp-
toms directly related to CD. This assessment estab-
lishes clinically relevant “cut points” with
questionnaires that may help physicians in optimiz-
ing treatment with onabotulinumtoxinA based on
the severity of symptoms.
Patient-reported outcomes are assessed using a variety
of questionnaires that evaluate symptoms and the
impact of CD-associated symptoms on their daily living
and are as follows:
1. Pain Numeric Rating Scale (PNRS) is a single-item
questionnaire of the current level of pain on a scale
from 0 to 10 [26].
2. Post-injection pain questionnaire is a 2-item ques-
tionnaire that assesses if neck pain was relieved dur-
ing the month after onabotulinumtoxinA injection.
If some pain relief occurred, subjects are asked to
Table 1 Information collected to characterize the treating physician’s practice site and experience in using botulinum
toxin for CD
Physician specialty ○ Neurologist
○ Physical medicine and rehabilitation
○ General practitioner
○ Pain specialist
Type of practice ○ Private, academic, health maintenance organization, general neurology, movement disorders
focused
○ Total number of patients seen per week
○ Number of CD patients per week
○ Total number of CD patients in practice
Experience in practice and with botulinum toxin
for CD
○ Years of treating CD with botulinum toxin
○ Clinical research experience with botulinum toxin
○ Formal botulinum toxin injection training
○ Years in practice
○ Board certification
CD: cervical dystonia.
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provide the number of days after injection before
they experienced relief of neck pain.
3. Patient Global Impression of Change (PGIC) is a
general questionnaire that assesses the change in
health status since the start of the study using a 7-
point scale ranging from “very much improved” to
“very much worse.” It provides insight into the clini-
cal value of the treatment [27].
4. Cervical Dystonia Impact Profile (CDIP-58) is a
validated, disease-specific questionnaire that mea-
sures quality of life using 58 items that form 8 dis-
tinct subscales (head and neck, pain and discomfort,
upper limb activities, walking, sleep, annoyance,
mood, and psychological). It is more sensitive in
detecting statistical and clinical change than compar-
able subscales of the SF-36, Functional Disability
Scale, and Pain and Activities of Daily Living sub-
scales of the TWSTRS [20,28].
5. Healthcare utilization questionnaire was developed
for this study and is used to assess the use of health-
care resources (doctor and allied healthcare visits,
emergency department visits, and hospitalizations)
for treatment of CD symptoms.
6. Work productivity questionnaire prospectively eli-
cits information regarding employment status, effect
of CD on employment and productivity, and impact
of treatment in restoring employment status [29].
Subjects who do not achieve any relief in symptoms 1
month after the first injection are assessed for a cause
of the lack of response, according to routine medical
practice, and then appropriateness of therapy, site of
injection, dosage, and other factors are re-evaluated.
The unilateral brow injection testing or serum antibody
testing can be used to assess if toxin neutralizing antibo-
dies are the cause of the lack of response [30]. Subjects
are withdrawn from the study if they fail the brow test
or if neutralizing antibodies are present.
Safety and tolerability are documented at each visit,
with notation of the occurrence of adverse events, date
of onset and resolution (if applicable), severity (mild,
moderate, or severe), duration, frequency, relationship
to study treatment, remedial actions, and outcome.
Statistical analysis plan
The CD PROBE study design is a clinical registry; there-
fore, there is no prespecified hypothesis. Descriptive sta-
tistics and exploratory analyses of baseline and post-
treatment outcome data will be performed. All analyses


















































































































Figure 1 CD PROBE study design and assessment of physician-reported and patient-reported outcome measures. CD: cervical dystonia;
PNRS: Pain Numeric Rating Scale; CDIP-58: Cervical Dystonia Impact Profile; AE: adverse event; PGIC: Patient Global Impression of Change;
TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale; P-STRS: Pictorial Spasmodic Torticollis Rating Scale; CGIC: Clinician Global Impression
of Change.
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R Foundation for Statistical Computing; http://www.r-
project.org/).
Baseline results
As of February 4, 2011, 613 subjects have been enrolled
into CD PROBE from 76 centers across the United
States. Of the 77 principal investigators who have
enrolled patients into CD PROBE, 68 are neurologists, 8
are physical medicine and rehabilitation specialists, and
1 is a pain specialist. Baseline demographics and disease
characteristics have been tabulated for 609 subjects and
are shown in Table 2. Most subjects (63.7%) were botu-
linum toxin-naïve and only 2.5% had previously received
other forms of treatment (8 surgical denervation, 5 deep
brain stimulation, 1 phenol injection, and 1 muscle
resection surgery). Baseline information regarding the
impact of having CD on work productivity is shown in
Table 3.
Discussion
OnabotulinumtoxinA is a safe and effective treatment
for CD that improves the quality of life of sufferers
[20-22]. Multiple outcome measures, including those
assessed by patients and physicians, have been used to
demonstrate effectiveness. In CD PROBE, comprehen-
sive questionnaires, clinical rating scales, and other
assessments are used to optimize the information col-
lected. This large clinical registry of prospectively fol-
lowed patients will allow analyses of determinants of
outcome and adverse effects. Although onabotulinum-
toxinA has been shown to be generally well tolerated
with an acceptable adverse event profile, the occurrence
of troublesome side effects, such as muscular weakness
and dysphagia, and more systemic side effects, such as
occasional malaise and other flu-like symptoms [31],
may potentially lead to considerable disability and dis-
continuation of further treatment. Risk factors for the
occurrence of adverse effects will be evaluated.
The baseline demographics and clinical characteristics
of the CD PROBE population suggest that this cohort is
representative of the general population with CD
[32,33]. As previously reported [34-38], symptoms of
CD typically emerge in the fifth decade of life and the
disorder is more frequent in women than in men. In
our population of 613 CD subjects, 63.7% of whom
were never treated with botulinum toxin, the mean age
at symptom onset was 48.3 ± 16.2 years, and the average
duration of symptoms was 5.4 ± 8.6 years. The disabling
nature of CD is supported by the findings that 36.6%




n (%) or mean ± SD
(range)
Gender, female 462 (75.9)






Native American 1 (0.2)
Other 1 (0.2)
BMI, kg/m2 26.4 ± 5.4
Age at CD symptom onset, y (n = 608) 48.3 ± 16.2 (0.0-89.3)
Time from CD onset to CD diagnosis, y (n
= 608)
5.4 ± 8.6 (-0.3-53.7)
Time to CD treatment after diagnosis, y (n
= 608)
1.0 ± 3.5 (-0.3-31.4)
Total TWSTRS (n = 604) 38.2 ± 13.2 (4-077.0)
*Number of patients with data was 609 unless otherwise specified. SD:
standard deviation; BMI: body mass index; CD: cervical dystonia; TWSTRS:
Toronto Western Spasmodic Torticollis Rating Scale.
Table 3 Work productivity assessment of patients at baseline
Work productivity assessment No. of patients Response, n (%) or mean ± SD
Employed at baseline 575 Yes: 262 (45.6)
Employed when CD symptoms began 313 Yes: 161 (51.4)
Stopped working due to CD 161 Yes: 59 (36.6)
Employment status affected by CD 262 • Different job with less responsibility or pay: 14 (5.3)
• Same job, reduced hours or responsibility: 50 (19.1)
• No change: 198 (75.6)
Missed work in past month due to CD 261 Yes: 74 (28.4)
Number of missed work days in past month 74 5.7 ± 11.6
Decreased productivity due to CD 261 Yes: 150 (57.5)
Estimated decrease in work productivity (%) 150 72.1 ± 20.5
Have received disability benefits due to CD 262 Yes: 12 (4.6)
Duration of disability benefits (months) 12 33.2 ± 60.8
CD: cervical dystonia; SD: standard deviation.
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stopped working because of CD, 28.4% missed work
because of CD in the past month (the average number
of days missed was 5.7 days), and 57.5% felt that their
productivity was decreased due to CD (Table 3).
Large clinical registries, such as CD PROBE, can
inform clinical practice by providing substantial
amounts of data; however, they also have inherent lim-
itations. The lack of a controlled design and a prespeci-
fied statistical analysis plan leaves the ability to answer
clinical questions with statistical power to chance; there-
fore, large numbers of subjects are needed. By not con-
trolling the inclusion/exclusion of patients in clinical
registries, it is more likely that subjects with comorbid
conditions will be included compared with those typi-
cally enrolled in controlled trials. Nonetheless, clinical
registries may provide data on the clinical nuances of
treatment that are not generally obtainable from rando-
mized controlled trials and, therefore, are more repre-
sentative of the “real-world” experience.
CD PROBE is anticipated to provide clinically relevant
information about disease-specific outcomes following
treatment with onabotulinumtoxinA, including reduc-
tion in pain, change in disease severity, CD-related qual-
ity of life, impact of treatment on overall health, and
economic aspects of CD, including healthcare utilization
and work productivity. The data generated from the
study is anticipated to answer a number of questions
regarding the optimal use of onabotulinumtoxinA for
CD or generate hypotheses for investigation, with the
ultimate goal to provide refinements in treatment to
further improve outcomes in CD treatment.
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